Media
Novartis Oncology Press Releases ›
Featured Content
03-Oct-2011
Novartis drug Glivec® shows significant overall survival benefit for patients with GIST after three years of adjuvant treatment vs. one year
"This study confirms the hypothesis that extending the duration of Glivec treatment for patients following surgery improves recurrence-free survival. For the first time, an effect on overall survival was found," said Heikki Joensuu, M.D., Ph.D., Professor, Oncology, University of Helsinki and principal investigator of the study. "Results from this trial may positively impact clinical practice by helping physicians create the optimal treatment plan for patients with operable KIT+ GIST."
04-Jun-2011
Novartis JAK inhibitor INC424 shows significant clinical benefit for myelofibrosis patients in two Phase III studies at ASCO
"These data show that INC424 may offer a significant advance in treating patients impacted by myelofibrosis, a serious malignant disease with limited available treatment options," said Alessandro Vannucchi, MD, Professor, Department of Hematology, University of Florence, Hospital Careggi, Italy, investigator for the COMFORT-II study.
Click on the titles below to view the complete Novartis Oncology abstracts that will be part of ASCO's 2010 Annual Meeting.
5-Jun-2010
2:00 p.m. CDT - Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT)
4:00 p.m. CDT - Everolimus for subependymal giant-cell astrocytomas (SEGAs) in tuberous sclerosis (TS)
View Materials Related to Products:
Research
Novartis Oncology is at the forefront of the discovery of new and better therapies. Explore our active pipeline and the many ways in which we strive to improve and extend patient lives.
SEARCH OUR WEBSITES
CONTACT
For information about Novartis Oncology, please contact:
novartis.com
ABOUT NOVARTIS ONCOLOGY
We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.
